Loading...
In the past 18 months, multiple randomized clinical trials have revealed outcome advantages for patients with heart failure with reduced ejection fraction (HFrEF) who received sodium–glucose cotransporter-2 (SGLT-2) inhibitors — including patients who did not have diabetes.
In the DAPA-HF trial, investigators compared dapagliflozin (Farxiga) and placebo in nearly 5000 patients with HFrEF, and in the EMPEROR-Reduced trial, researchers assessed empagliflozin (Jardiance) in nearly 4000 patients with HFrEF. Participants were followed for about 18 months, and half of patients in each trial did not have diabetes. Each trial demonstrated benefit in various composite outcomes, and each study individually showed significantly lower rates of first hos…